Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report
RATIONALE: Dacomitinib-induced liver injury is often manifested by mild elevations of transaminases and bilirubin, and severe intrahepatic cholestasis caused by dacomitinib for simultaneous taking orally cytochrome P450 2D6 (CYP2D6) competitive substrates has been rarely reported. PATIENT CONCERNS:...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
NLM (Medline)
2022
|
Online Access: | View Fulltext in Publisher |